PDCD1 and melanoma: In the examination of transcriptome sequencing data before and after treatment with nivolumab (PD-1/CTLA-4 antibodies) in 105 advanced melanoma patients, those who responded to the therapy (23 cases) showed significantly higher GZMK expression (P < 0.05) (Fig. 7C).